Synergy Pharmaceuticals buy tamam
Start price
06.10.15
/
50%
€5.93
Target price
06.04.16
€10.82
Performance (%)
-57.53%
End price
06.04.16
€2.52
Summary
This prediction ended on 06.04.16 with a price of €2.52. Massive losses of -57.53% were the result for the BUY prediction by tamam. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Synergy Pharmaceuticals | - | - | - | - |
| iShares Core DAX® | 0,41 % | 8,82 % | 12,26 % | 49,53 % |
| iShares Nasdaq 100 | 3,68 % | 10,82 % | 44,02 % | 96,25 % |
| iShares Nikkei 225® | 2,70 % | 15,25 % | 48,04 % | 64,69 % |
| iShares S&P 500 | 2,44 % | 7,93 % | 33,00 % | 67,57 % |
Comments by tamam for this prediction
In the thread Synergy Pharmaceuticals diskutieren
It seems logical to imagine SGYP as a takeover candidate, because
Synergy represents a late-stage, highly risk-mitigated and undervalued name in the biotech sector, as its lead candidate plecanatide has already completed two pivotal Phase 3 trials in chronic idiopathic constipation (CIC) successfully and is slated to be filed for approval by the end of this year.
With ~45 million Americans suffering from chronic constipation and IBS, and companies like Allergan (NYSE:AGN) and Valeant (NYSE:VRX) focusing their marketing efforts on GI treatments, it seems logical to imagine SGYP as a takeover candidate.
(Laufzeit überschritten)
Stopped prediction by tamam for Synergy Pharmaceuticals
Synergy Pharmaceuticals
Start price
Target price
Perf. (%)
€2.34
25.09.17
25.09.17
€6.31
13.12.18
13.12.18
-94.98%
13.12.18
13.12.18
Synergy Pharmaceuticals
Start price
Target price
Perf. (%)
€4.56
18.03.17
18.03.17
€11.28
22.05.17
22.05.17
-21.74%
22.05.17
22.05.17